Phase 2 N=24 Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)
Parkinson Disease
Primary: Change From Baseline in MDS-UPDRS Part II. — 10.00; 7.33; -1.87; 0.11 score on a scale (52 points total)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=90 Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal
Opioid Withdrawal
Primary: Subjective Opioid Withdrawal Scale-Gossop (SOWS) Scale Score — 7.0; 9.1 score on a scale — p=.05
Phase 2 N=116 Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
Respiratory Syncytial Virus
Primary: Panel A vs Panel C: Peak Viral Load (PVL) Determined by Viral Quantitative Culture — 2.55; 2.84 log10 plaque forming units (PFU)/mL — p=0.578
Phase 2 N=24 QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
Chordoma
Primary: Overall Response Rate — 1; 1 Participants
Phase 2 N=54 Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Number of Participants Evaluated for Hematologic and Nonhematologic Toxicities as Measured by NCI CTC v2.0 — 5; 14; 7; 28 Participants
Phase 2 N=153 To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A — 0; 0; 0 Participants
Phase 2 N=17 Brentuximab Vedotin for Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis · Scleroderma · dcSSc
Primary: Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. — 0.333; 0.000; 0.571; 0.000 Proportion of participants…
Phase 2 N=58 An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva
Primary: Parts A and B: Percentage of Flare-ups With No New Heterotopic Ossification (HO) at Week 12 — 64.3; 72.5 percentage of flare-ups
Phase 2 N=51 Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
HIV Infections · Non-Alcoholic Fatty Liver Disease
Primary: Change (Absolute) in IHTG (%) — -4.24 IHTG % — p=<0.001
Phase 2 N=100 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Diffuse Large B-Cell Lymphoma · B-cell Non-Hodgkin's Lymphoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 16; 8; 12; 32 Participants
Phase 2 N=55 Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
Chemotherapy-induced Neutropenia
Primary: DSN — 0.15; 0.36; 0.43; 0.29 days
Phase 2 N=5 Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
Tuberous Sclerosis Complex · Epilepsy
Primary: Safety - Adverse Events — 40 percentage of participants
Phase 2 N=65 Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
Diabetic Macular Edema (DME)
Primary: Systemic Safety and Tolerability of a Single IVT Injection of UBX1325. — 4; 5; 9; 0 Participants
Phase 2 N=13 A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Solid Tumor · Lymphoma · Osteosarcoma
Primary: Number of Patients With Dose-Limiting Toxicities (DLT) — 0; 2 Participants
Phase 2 N=49 Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants